2-[7-(1,2-dihydrotriazol-3-yl)-4-fluoro-1H-pyrrolo[2,3-c]pyridin-3-yl]-2-oxoacetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 2-[7-(1,2-dihydrotriazol-3-yl)-4-fluoro-1H-pyrrolo[2,3-c]pyridin-3-yl]-2-oxoacetic acid
• 化学式: C₁₁H₈FN₅O₃
• 分子量: 277.21
• InChiKey: IZYAIGATNJGZIX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  110
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES
  申请人：Bristol-Myers Squibb Company

  公开号：EP2975038A1

  公开（公告）日：2016-01-20

  This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and their use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS.

  本发明提供了具有药物和生物影响特性的化合物、其药物组合物及其用途。本发明尤其涉及氮杂吲哚氧乙酰哌嗪衍生物。这些化合物具有独特的抗病毒活性，无论是单独使用还是与其它抗病毒药、抗感染药、免疫调节剂或 HIV 进入抑制剂联合使用。更具体地说，本发明涉及可用于治疗 HIV 和 AIDS 的化合物。
• Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
  申请人：Bristol-Myers Squibb Company

  公开号：EP2497770B1

  公开（公告）日：2014-05-14
• ALKYL AMIDES AS HIV ATTACHMENT INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP2646439B1

  公开（公告）日：2016-05-25
• THIOAMIDE, AMIDOXIME AND AMIDRAZONE DERIVATIVES AS HIV ATTACHMENT INHIBITORS
  申请人：VIIV Healthcare UK (No.5) Limited

  公开号：EP2696937B1

  公开（公告）日：2017-05-17
• SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS
  申请人：VIIV HEALTHCARE UK (NO.4) LIMITED

  公开号：US20190111066A1

  公开（公告）日：2019-04-18

  This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R 1 does not exist; W is C or N with the proviso that when W is N, R 2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C 1 -C 6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.